Cerus Corporation
Cerus Corporation, a leading biotechnology firm headquartered in the United States, has been at the forefront of blood safety and transfusion medicine since its founding in 1991. With a strong operational presence across North America and Europe, Cerus is dedicated to developing innovative solutions that enhance the safety of blood products. The company’s flagship product, the INTERCEPT Blood System, utilises advanced pathogen inactivation technology, setting it apart in the industry. This system significantly reduces the risk of transfusion-transmitted infections, making it a vital tool for healthcare providers. Cerus has achieved notable milestones, including regulatory approvals and partnerships that underscore its commitment to improving patient outcomes. As a pioneer in blood safety, Cerus Corporation continues to solidify its market position through ongoing research and development, ensuring the highest standards in transfusion practices.
DitchCarbon Score
How does Cerus Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cerus Corporation's score of 22 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cerus Corporation's reported carbon emissions
In 2022, Cerus Corporation reported total carbon emissions of approximately 30,498,000 kg CO2e. This figure includes Scope 1 emissions of about 223,000 kg CO2e, Scope 2 emissions of approximately 473,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled around 29,802,000 kg CO2e. The Scope 3 emissions breakdown reveals that the largest sources were from purchased goods and services (approximately 21,999,000 kg CO2e) and upstream transportation and distribution (about 5,664,000 kg CO2e). Despite the substantial emissions, Cerus Corporation has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. As a leader in the medical technology sector, Cerus Corporation's future climate actions will be crucial in addressing industry-wide challenges related to carbon emissions and climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 223,000 |
| Scope 2 | 473,000 |
| Scope 3 | 29,802,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cerus Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
